LPCN Overview
Upcoming Projects (LPCN)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (LPCN)
-
Discussing the recent Phase 2 data on Lipocene's LPCN 2401 in patients with obesity with a focus on body composition and muscle mass
Ticker: LPCN
Executed On: May 10, 2024 at 10:00 AM EDT -
Discussing Antares's and Lipocine's TLANDO for testosterone replacement therapy, following its receipt of US FDA approval March 29, 2022
Tickers: ATRS, LPCN, HALO
Executed On: Apr 13, 2022 at 04:00 PM EDT
Expired Projects (LPCN)
-
With the recent delay on TLando's approval, a conversation about the market potential if approved.
Tickers: LPCN, Clarus Therapeutics
Execute By: Dec 09, 2020
Upcoming & Overdue Catalysts (LPCN)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (LPCN)
-
Lipocine (LPCN) Announces Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects
Ticker: LPCN
Occurred on: Jan 12, 2021 -
Lipocine (LPCN) receives FDA CRL for the 2nd time regarding its refiled MA for testosterone replacement therapy candidate Tlando
Ticker: LPCN
Occurred on: Nov 11, 2019 -
FDA Completes Post Action Meeting with Lipocine (LPCN) Regarding LPCN 1021 in Testosterone Replacement Therapy
Ticker: LPCN
Occurred on: Oct 17, 2016 -
Lipocine (LPCN) Releases Phase 2b Results for Oral Testosterone Replacement Therapy LPCN 1111
Ticker: LPCN
Occurred on: Sep 26, 2016 -
PDUFA June 28 2016 of LPCN 1021 for men with low testosterone
Ticker: LPCN
Occurred on: Jun 29, 2016
Strategic Initiatives (LPCN)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
